Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance

BACKGROUND: Eculizumab, a humanized monoclonal antibody targeted to terminal complement protein C5, is approved in Japan for treatment of patients with anti-acetylcholine receptor antibody-positive (AChR+) generalized myasthenia gravis (gMG) whose symptoms are difficult to control with high-dose int...

Descripción completa

Detalles Bibliográficos
Autores principales: Murai, Hiroyuki, Suzuki, Shigeaki, Hasebe, Miki, Fukamizu, Yuji, Rodrigues, Ema, Utsugisawa, Kimiaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970258/
https://www.ncbi.nlm.nih.gov/pubmed/33796147
http://dx.doi.org/10.1177/17562864211001995

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970258/
https://www.ncbi.nlm.nih.gov/pubmed/33796147
http://dx.doi.org/10.1177/17562864211001995

Ejemplares similares